Patritumab Deruxtecan Biosimilar Antibody-Drug Conjugate (HER3) for Research
Cat No.: GMP-Bios-INN-946
Pre-made Patritumab Deruxtecan benchmark antibody (Whole mAb ADC, anti-ERBB3/Erbb-3 therapeutic antibody, Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-946-1mg | 1mg | |
| GMP-Bios-INN-946-10mg | 10mg | |
| GMP-Bios-INN-946-100mg | 100mg | |
| GMP-Bios-INN-946-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Patritumab Deruxtecan Biosimilar, Whole Mab Adc, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody Drug Conjugate |
| INN Name | Patritumab Deruxtecan |
| Target | ERBB3/Erbb-3 |
| Format | Whole mAb ADC |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Daiichi Sankyo Inc. (Edison NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |

